Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samit Hirawat

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 2014
Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKTNeil A O'Brien, Karen McDonald, Luo Tong, et al.
Lancet (London, England)|August 30, 2008
Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trialEitan Kerem, Samit Hirawat, Shoshana Armoni, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|April 5, 2011
Ambulatory quantitative waking and sleeping cough assessment in patients with cystic fibrosisEitan Kerem, Michael Wilschanski, Nilsen L Miller, et al.
Breast Cancer Research : BCR|August 16, 2020
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancerNeil A O'Brien, Martina S J McDermott, Dylan Conklin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2014
Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapyCristina Saura, Johanna Bendell, Guy Jerusalem, et al.
American Journal of Respiratory and Critical Care Medicine|July 13, 2010
Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosisIsabelle Sermet-Gaudelus, Kris De Boeck, Georges J Casimir, et al.
The New England Journal of Medicine|May 16, 2019
Alpelisib for <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive Advanced Breast CancerFabrice André, Eva Ciruelos, Gabor Rubovszky, et al.
The Lancet. Oncology|January 30, 2017
Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trialDenis Soulières, Sandrine Faivre, Ricard Mesía, et al.
The Lancet. Oncology|May 29, 2018
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trialDebu Tripathy, Seock-Ah Im, Marco Colleoni, et al.
The New England Journal of Medicine|October 9, 2016
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast CancerGabriel N Hortobagyi, Salomon M Stemmer, Howard A Burris, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 2014
Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKTNeil A O'Brien, Karen McDonald, Luo Tong, et al.
Lancet (London, England)|August 30, 2008
Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trialEitan Kerem, Samit Hirawat, Shoshana Armoni, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|April 5, 2011
Ambulatory quantitative waking and sleeping cough assessment in patients with cystic fibrosisEitan Kerem, Michael Wilschanski, Nilsen L Miller, et al.
Breast Cancer Research : BCR|August 16, 2020
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancerNeil A O'Brien, Martina S J McDermott, Dylan Conklin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2014
Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapyCristina Saura, Johanna Bendell, Guy Jerusalem, et al.
American Journal of Respiratory and Critical Care Medicine|July 13, 2010
Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosisIsabelle Sermet-Gaudelus, Kris De Boeck, Georges J Casimir, et al.
The New England Journal of Medicine|May 16, 2019
Alpelisib for <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive Advanced Breast CancerFabrice André, Eva Ciruelos, Gabor Rubovszky, et al.
The Lancet. Oncology|January 30, 2017
Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trialDenis Soulières, Sandrine Faivre, Ricard Mesía, et al.
The Lancet. Oncology|May 29, 2018
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trialDebu Tripathy, Seock-Ah Im, Marco Colleoni, et al.
The New England Journal of Medicine|October 9, 2016
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast CancerGabriel N Hortobagyi, Salomon M Stemmer, Howard A Burris, et al.
Pageof 3